The patient continues to be clinically well for 12 months after CART‐19 plus anti‐PD‐L1 administration.26 Hence, inhibition of immunosuppressive factors could enhance the activity of CART‐19 in malignancy, especially solid tumor, thanks to more complicated TME of neoplasm have than leukemia. The gene discussed is CD274; the disease is neoplasm.